Ocular Therapeutix, Inc. (NASDAQ:OCUL) is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.24 per share.
For the full year, analysts predict revenues of $ 19.94 million, while looking forward to loss of $ 1.44 per share.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 5.80 million ~ $ 5.90 million
Click Here For More Historical Outlooks Of Ocular Therapeutix, Inc.
Previous Quarter Performance
Ocular Therapeutix, Inc. came out with loss for the second quarter of $ 0.64 per share, from the revenue of $ 1.57 million. The quarterly revenues up 141.54 percent compared with the same quarter last year. According to street consensus, OCUL was expected to report 2Q20 loss of $ 0.31 per share from revenue of $ 1.50 million. The bottom line results missed street analysts by $ 0.33 or 106.45 percent, at the same time, top line results outshined analysts by $ 0.07 million or 4.67 percent.
Stock Performance
Shares of Ocular Therapeutix, Inc. traded up $ 1.51 or 14.33 percent on Wednesday, reaching $ 12.05 with volume of 2.00 million shares. Ocular Therapeutix, Inc. has traded high as $ 12.19 and has cracked $ 10.95 on the downward trend
The closing price of $ 12.05, representing a 328.46 % increase from the 52 week low of $ 2.46 and a 15.14 % decrease over the 52 week high of $ 12.42.
The company has a market capital of $ 859.50 million and is part of the Healthcare sector and Biotechnology industry.
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases.
